- Home
- TYRA vs SANA Comparison
TYRA vs SANA Comparison
Compare TYRA & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- SANA
- Stock Information
- Founded
- TYRA 2018
- SANA 2018
- Country
- TYRA United States
- SANA United States
- Employees
- TYRA N/A
- SANA N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- SANA Medicinal Chemicals and Botanical Products
- Sector
- TYRA Health Care
- SANA Health Care
- Exchange
- TYRA Nasdaq
- SANA Nasdaq
- Market Cap
- TYRA 576.6M
- SANA 519.8M
- IPO Year
- TYRA 2021
- SANA 2021
- Fundamental
- Price
- TYRA $9.52
- SANA $2.32
- Analyst Decision
- TYRA Strong Buy
- SANA Strong Buy
- Analyst Count
- TYRA 7
- SANA 5
- Target Price
- TYRA $30.86
- SANA $9.50
- AVG Volume (30 Days)
- TYRA 298.0K
- SANA 3.9M
- Earning Date
- TYRA 05-08-2025
- SANA 05-08-2025
- Dividend Yield
- TYRA N/A
- SANA N/A
- EPS Growth
- TYRA N/A
- SANA N/A
- EPS
- TYRA N/A
- SANA N/A
- Revenue
- TYRA N/A
- SANA N/A
- Revenue This Year
- TYRA N/A
- SANA N/A
- Revenue Next Year
- TYRA N/A
- SANA N/A
- P/E Ratio
- TYRA N/A
- SANA N/A
- Revenue Growth
- TYRA N/A
- SANA N/A
- 52 Week Low
- TYRA $6.42
- SANA $1.26
- 52 Week High
- TYRA $29.60
- SANA $8.17
- Technical
- Relative Strength Index (RSI)
- TYRA 45.60
- SANA 60.42
- Support Level
- TYRA $8.88
- SANA $2.11
- Resistance Level
- TYRA $9.68
- SANA $2.35
- Average True Range (ATR)
- TYRA 0.64
- SANA 0.20
- MACD
- TYRA -0.08
- SANA 0.04
- Stochastic Oscillator
- TYRA 26.98
- SANA 81.33
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.